This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.
Approval for implementation of everolimus bht manufactured at a new manufacturing site.
Device | Absorb GT1 Bioresorbable Vascular Scaffold (BVS) System |
Classification Name | Absorbable Coronary Drug-eluting Stent |
Generic Name | Absorbable Coronary Drug-eluting Stent |
Applicant | ABBOTT VASCULAR INC. |
Date Received | 2018-03-01 |
Decision Date | 2018-05-30 |
PMA | P150023 |
Supplement | S010 |
Product Code | PNY |
Docket Number | Premarket Approval (PMA) // Quick Links: Skip To Main Page Content Skip To Search Skip To Topics Menu Skip To Common Links U.S. Food & Drug Administration Follow FDA En Español Search FDA Home Food Drugs Medical Devices Radia |
Advisory Committee | Cardiovascular |
Supplement Type | Normal 180 Day Track |
Supplement Reason | Process Change - Manufacturer/sterilizer/packager/supplier |
Expedited Review | No |
Combination Product | Yes |
Applicant Address | ABBOTT VASCULAR INC. 3200 Lakeside Drive santa Clara, CA 95054 |
Supplement Number | Date | Supplement Type |
---|---|---|
P150023 | Original Filing | |
S010 | 2018-03-01 | Normal 180 Day Track |
S009 | 2017-05-17 | 30-day Notice |
S008 | 2017-04-14 | 30-day Notice |
S007 | 2017-03-13 | 135 Review Track For 30-day Notice |
S006 | 2016-10-24 | 30-day Notice |
S005 | 2016-09-08 | 30-day Notice |
S004 | ||
S003 | 2016-08-05 | Normal 180 Day Track No User Fee |
S002 | 2016-07-29 | Special (immediate Track) |
S001 | 2016-07-11 | Normal 180 Day Track |